LNF2105 not checked

Shandong New Time Pharmaceutical Co., LTD

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“The dosage of LNF2105 was increased sequentially from 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.0 mg/kg, 3.0 mg/kg, to 4.5 mg/kg.”In the company’s words, NCT07661797 on ClinicalTrials.gov
Tested for
Patients With Advanced Solid Tumors
Main trialPhase 1
“This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.”In the company’s words, NCT07661797 on ClinicalTrials.gov

Other drugs for Patients With Advanced Solid Tumors

All 302 drugs for Patients With Advanced Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Jun 2028 Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LNF2105

Following is part of Solo: you see every change to LNF2105 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in